2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.113 (Poster) Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

PP01.113 (Poster) Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

Back to course

Pdf Summary

The preliminary results of the EVOKE-02 study evaluating sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) as a first-line treatment for metastatic non-small cell lung cancer (mNSCLC) were reported. In cohort A (patients with PD-L1 tumor proportion score [TPS] 50%), the objective response rate (ORR) was 69%, and the disease control rate (DCR) was 86%. In cohort B (patients with PD-L1 TPS <50%), the ORR was 44%, and the DCR was 78%. The responses were rapid and durable, with a median duration of response (DOR) that was not reached, and a DOR rate at 6 months of 88% in both cohorts. The mean time to response in patients who achieved a partial response was 1.8 months for cohort A and 1.7 months for cohort B. The safety profile of SG Pembro was manageable, with a low rate of treatment discontinuation due to treatment-emergent adverse events (18%). These preliminary results suggest that SG Pembro may be an effective and well-tolerated first-line treatment option for patients with mNSCLC, warranting further investigation. The ongoing Phase 3 EVOKE-03 study is evaluating SG Pembro versus Pembro monotherapy in untreated mNSCLC patients with PD-L1 TPS 50%.

Asset Subtitle

Jyoti Patel

Keywords

EVOKE-02 study

sacituzumab govitecan

pembrolizumab

metastatic non-small cell lung cancer

cohort A

cohort B

objective response rate

disease control rate

duration of response

Phase 3 EVOKE-03 study